SOB100
Phase 1Small molecule
SOB100 is one of 39 small molecule programs targeting TED. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in TED
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Alecensa
RocheApproved
Scemblix
NovartisApproved
Medrol
PfizerPhase 3
Rituxan
RochePhase 3
Calquence
AstraZenecaPhase 3
Golytely
BayerPhase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Fludara
SanofiPhase 2
Eliquis
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SOB100. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SShine-On Biomedical Co., Ltd.